Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · IEX Real-Time Price · USD
1.530
-0.300 (-16.39%)
Jul 22, 2024, 11:25 AM EDT - Market open
Salarius Pharmaceuticals Employees
Salarius Pharmaceuticals had 2 employees as of December 31, 2023. The number of employees decreased by 10 or -83.33% compared to the previous year.
Employees
2
Change (1Y)
-10
Growth (1Y)
-83.33%
Revenue / Employee
n/a
Profits / Employee
-$4,458,605
Market Cap
1.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Assure Holdings | 95 |
China SXT Pharmaceuticals | 78 |
LogicMark | 27 |
Biodexa Pharmaceuticals | 21 |
Bluejay Diagnostics | 10 |
SCWorx | 9 |
Dermata Therapeutics | 8 |
GRI Bio | 4 |
SLRX News
- 5 weeks ago - Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire
- 4 months ago - Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment - GlobeNewsWire
- 9 months ago - Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire